These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 163862)

  • 1. Lysis of tumor cells by antibody and complement. II. Lack of correlation between amount of C4 and C3 fixed and cell lysis.
    Ohanian SH; Borsos T
    J Immunol; 1975 Apr; 114(4):1292-5. PubMed ID: 163862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of antibody-complement-mediated killing of tumor cells by hormones.
    Schlager SI; Ohanian SH; Borsos T
    Cancer Res; 1976 Oct; 36(10):3672-7. PubMed ID: 182362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemical quantitaion of the third component of guinea pig complement in fluid phase and bound to cell surfaces.
    Ohanian SH; Borsos T
    J Immunol; 1975 Jan; 114(1 Pt 2):326-30. PubMed ID: 1167878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of concanavalin A on the killing of tumor cells by antibody and complement.
    Boyle MD; Langone JJ; Ohanian SH; Borsos T
    J Immunol; 1977 May; 118(5):1626-30. PubMed ID: 192797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis.
    Boyle MD; Ohanian SH; Borsos T
    J Immunol; 1975 Aug; 115(2):473-5. PubMed ID: 50364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the ability of tumor cells to incorporate specific fatty acids and their sensitivity to killing by a specific antibody plus guinea pig complement.
    Schlager SI; Ohanian SH; Borsos T
    J Natl Cancer Inst; 1978 Sep; 61(3):931-4. PubMed ID: 278869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of hormone-induced tumor cell resistance to killing by antibody and complement.
    Schlager SI; Ohanian SH; Borsos T
    Cancer Res; 1977 Mar; 37(3):765-70. PubMed ID: 189914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-dependent cytotoxic antitumor antibody. II. Quantitative determination of cell-bound immunoglobulin M1.
    Boyle MD; Langone JJ
    J Natl Cancer Inst; 1979 Jun; 62(6):1537-44. PubMed ID: 286124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
    Schreiber AD; Frank MM
    J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing effect by metabolic inhibitors on the killing of tumor cells by antibody and complement.
    Segerling M; Ohanian SH; Borsos T
    Cancer Res; 1975 Nov; 35(11 Pt 1):3195-203. PubMed ID: 52404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysis of tumor cells by antibody and complement. VII. Complement-dependent 86Rb release--a nonlethal event?
    Boyle MD; Ohanian SH; Borsos T
    J Immunol; 1976 Oct; 117(4):1346-50. PubMed ID: 185297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of metabolic inhibitors on the ability of tumor cells to express antigen and bind complement components C4 and C3.
    Segerling M; Ohanian SH; Borsos T
    Cancer Res; 1975 Nov; 35(11 Pt 1):3204-8. PubMed ID: 52405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immunostimulation. IV. Role of complement.
    Shearer WT; Atkinson JP; Frank MM; Parker CW
    J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. I. Evidence for the existence of an intermediate, T.
    Boyle MD; Ohanian SH; Borsos T
    J Immunol; 1976 May; 116(5):1272-5. PubMed ID: 178793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemical quantitation of cell bound C4.
    Ohanian SH; Borsos T
    J Immunol; 1974 Mar; 112(3):979-86. PubMed ID: 4359786
    [No Abstract]   [Full Text] [Related]  

  • 17. Specific lysis of human colon tumor cells by antibodies to CEA and isoantigen A: dependence on rabbit serum or neuraminidase.
    Tompkins WA; Seth PB; Yip DM; Palmer JL; Gee SR; Rawls WE
    J Immunol; 1976 Nov; 117(5 Pt.2):1943-8. PubMed ID: 792333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
    Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
    J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic relationship between the fourth component of human and guinea pig complement.
    Ohanian SH; Borsos T
    J Immunol; 1975 Jan; 114(1 Pt 1):161-4. PubMed ID: 46239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C.
    Schlager SI; Ohanian SH; Borsos T
    J Immunol; 1978 Mar; 120(3):895-901. PubMed ID: 632591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.